Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Dr. Martin Mackay is the Co-Founder and CEO of Rallybio, a biotech start-up dedicated to developing transformative treatments for patients with rare and ultra-rare diseases.
Martin is a Co-Founder and Chairman of Rallybio and has worked in pharmaceutical and biotech R&D for more than 30 years, holding leadership roles at companies including Pfizer, AstraZeneca, and Alexion. He is currently a member of the Board of Directors of Charles River Laboratories and Springworks Therapeutics. He is also a Scientific Advisor at Pivotal BioVenture Partners and on the External Advisory Board of Boston Children’s Hospital. Martin summarizes the three loves in his life as being family, work, and soccer, but not necessarily in that order.
Martin obtained a First-Class Honors Degree in microbiology from Heriot-Watt University and his Ph.D. in molecular genetics from the University of Edinburgh.
